Lutathera (177Lutetium 177-DOTATATE) is a recently FDA approved treatment option for metastatic neuroendocrine tumors of the stomach, gut or pancreas (GEP-NETs, sometimes also referred to as carcinoid tumors). Lutathera is the first type of Peptide Receptor Radionuclide Therapy (PRRT) approved by the U.S. Food and Drug Administration (FDA). Because UCLA treated the largest number of patients in the US with Lutathera as part of an expanded access clinical trial prior to FDA approval, UCLA clinicians already have significant experience with this therapy. Patients receiving Lutathera treatments have seen a demonstrated reduction in the risk of disease progression, with results similar to the trials that led to FDA approval of Lutathera.
Lutathera is a radiolabeled somatostatin analog, a cell-targeting protein (or peptide) called octreotide combined with a radionuclide (177Lutetium), creating a special type of radiopharmaceutical called a radiopeptide. When injected into the patient’s bloodstream, this radiopeptide travels binds to neuroendocrine tumor cells, delivering a targeted dose of therapeutic radiation to the tumor cells.
Our clinicians and faculty consist of renowned experts in the diagnosis and treatment of neuroendocrine tumors. Actively involved in research and clinical trials, UCLA is one of the few expanded access Investigational New Drug trial sites for PRRT, making UCLA a true center of excellence. Our multidisciplinary team of clinicians include nuclear medicine physicians, oncologists, endocrinologists, gastroenterologists, surgeons and interventional radiologists.
The PRRT team is dedicated to providing the best possible care for our patients each and every time. Our patients are at the center of everything that we do.
For more information, please call the number below and let our staff know that you are calling about the Lutathera therapy. You will then be directed to the most appropriate staff to help you with your inquiry:
